Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Harpreet Singh, Liam Wilson, Tom Tencer & Jinender Kumar. (2023) Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis. ClinicoEconomics and Outcomes Research 15, pages 125-138.
Read now
Read now
Rosanne W Meijboom, Liese Barbier, Louise C Druedahl, Kati Sarnola, Hanna M Tolonen, Helga Gardarsdottir, Toine C G Egberts & Thijs J Giezen. (2023) Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance. Expert Opinion on Biological Therapy 23:8, pages 801-817.
Read now
Read now
Hemlata Chhabra, Morgane C Mouslim, Smita Kashiramka & Anurag S Rathore. (2022) Dynamics of biosimilar uptake in emerging markets. Expert Opinion on Biological Therapy 22:6, pages 679-688.
Read now
Read now
Yeong Wook Song, Yong-Beom Park & Jinseok Kim. (2021) LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 21:1, pages 1-8.
Read now
Read now
Cécile Rémuzat, Anna Kapuśniak, Aleksandra Caban, Dan Ionescu, Guerric Radière, Cyril Mendoza & Mondher Toumi. (2017) Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. Journal of Market Access & Health Policy 5:1.
Read now
Read now
Articles from other publishers (49)
Hyunjung Woo, Gyeongseon Shin, Donghwan Lee, Hye-Young Kwon & SeungJin Bae. (2023) Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries. BioDrugs.
Crossref
Crossref
Sonia Gandhi, Smita Kashiramka & Anurag S. Rathore. (2023) Emerging themes and factors influencing the prices of biotherapeutics. World Medical & Health Policy 15:4, pages 613-637.
Crossref
Crossref
Kevin Wirth, Stefan Boes, Markus Näpflin, Carola Huber & Eva Blozik. (2023) Initial prescriptions and medication switches of biological products: an analysis of prescription pathways and determinants in the Swiss healthcare setting. BMJ Open 13:11, pages e077454.
Crossref
Crossref
Marion Tano, Pascal Paubel, Matthieu Ribault & Albane Degrassat-Théas. (2023) What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France. Applied Health Economics and Health Policy 21:5, pages 799-811.
Crossref
Crossref
Kyung-Bok Son. (2023) Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?. Frontiers in Public Health 11.
Crossref
Crossref
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto & Isabelle Huys. (2023) The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis. Health Research Policy and Systems 21:1.
Crossref
Crossref
Elif Car, Arnold G. Vulto, Mark Van Houdenhoven, Isabelle Huys & Steven Simoens. (2023) Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Frontiers in Pharmacology 14.
Crossref
Crossref
Roudy Sayah, Sanaa Awada, Lina Ismaiil & Georges Hatem. (2023) Assessment of the differences between generic and biosimilar drugs: A brief literature review. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, pages 174113432311573.
Crossref
Crossref
Yannick Vandenplas, Steven Simoens, Florian Turk, Arnold G. Vulto & Isabelle Huys. (2022) Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines. Applied Health Economics and Health Policy 20:6, pages 803-817.
Crossref
Crossref
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Florian Turk & Isabelle Huys. (2022) Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study. BMC Health Services Research 22:1.
Crossref
Crossref
Noraisyah Mohd Sani, Zoriah Aziz, Rema Panickar & Adeeba Kamarulzaman. (2022) Pharmacists’ Perspectives of Biosimilars: A Systematic Review. BioDrugs 36:4, pages 489-508.
Crossref
Crossref
Saana V. Luukkanen, Hanna M. Tolonen, Marja Airaksinen & Laura S. M. Saarukka. (2022) The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland. BioDrugs 36:4, pages 537-547.
Crossref
Crossref
Muna Oqal, Bushra Hijazi, Abdelrahim Alqudah, Ahmad Al-Smadi, Basima A Almomani, Roaa Alnajjar, Majd Abu Ghunaim, Mohammad Irshaid & Aroob Husam. (2022) Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan. International Journal of Clinical Practice 2022, pages 1-10.
Crossref
Crossref
Yannick Vandenplas, Liese Barbier, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto & Isabelle Huys. (2022) Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. Frontiers in Pharmacology 12.
Crossref
Crossref
Manvi Singh & Pratima R. Solanki. 2022. Biomedical Product and Materials Evaluation. Biomedical Product and Materials Evaluation
275
286
.
Ruth Oriama, Robert Mudida & Thierry Burger-Helmchen. 2022. Transdisciplinarity. Transdisciplinarity
249
266
.
Konstantin Tachkov, Zornitsa Mitkova, Petya Milushewa & Guenka Petrova. (2021) Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria. Healthcare 9:6, pages 697.
Crossref
Crossref
Louise C. Druedahl, Sofia Kälvemark Sporrong, Marco van de Weert, Marie Louise De Bruin, Hans Hoogland, Timo Minssen & Anna Birna Almarsdóttir. (2021) Evolving Biosimilar Clinical Requirements: A Qualitative Interview Study with Industry Experts and European National Medicines Agency Regulators. BioDrugs 35:3, pages 351-361.
Crossref
Crossref
Félix Lobo & Isabel Río-Álvarez. (2021) Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain. Pharmaceuticals 14:3, pages 283.
Crossref
Crossref
Konstantin Tachkov, Zornitsa Mitkova, Vladimira Boyadzieva & Guenka Petrova. (2021) Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria. Pharmaceuticals 14:1, pages 64.
Crossref
Crossref
Evelien Moorkens, Brian Godman, Isabelle Huys, Iris Hoxha, Admir Malaj, Simon Keuerleber, Silvia Stockinger, Sarah Mörtenhuber, Maria Dimitrova, Konstantin Tachkov, Luka Vončina, Vera Vlahović Palčevski, Gnosia Achniotou, Juraj Slabý, Leona Popelková, Kateřina Kohoutová, Dorthe Bartels, Ott Laius, Jaana E. Martikainen, Gisbert W. Selke, Vasileios Kourafalos, Einar Magnússon, Rannveig Einarsdóttir, Roisín Adams, Roberta Joppi, Eleonora Allocati, Arianit Jakupi, Anita Viksna, Ieva Greičiūtė-Kuprijanov, Patricia Vella Bonanno, Vincent Suttorp, Øyvind Melien, Robert Plisko, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Corinne Zara, Vanda Marković-Peković, Nataša Grubiša, Gustaf Befrits, Robert Puckett & Arnold G. Vulto. (2021) The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Frontiers in Pharmacology 11.
Crossref
Crossref
Gregory Reardon. 2020. Biologics, Biosimilars, and Biobetters. Biologics, Biosimilars, and Biobetters
195
212
.
Brian G. Feagan, Mona Marabani, Jashin J. Wu, Freddy Faccin, Claire Spronk & Gilberto Castañeda-Hernández. (2020) The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. Advances in Therapy 37:11, pages 4491-4518.
Crossref
Crossref
Evelien Moorkens, Teresa Barcina Lacosta, Arnold G. Vulto, Martin Schulz, Gabriele Gradl, Salka Enners, Gisbert Selke, Isabelle Huys & Steven Simoens. (2020) Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. Pharmaceuticals 13:10, pages 324.
Crossref
Crossref
Maria Chiara Ditto, Simone Parisi, Marta Priora, Silvia Sanna, Clara Lisa Peroni, Angela Laganà, Antonio D’Avolio & Enrico Fusaro. (2020) Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. Scientific Reports 10:1.
Crossref
Crossref
Hye-Jae Lee, Euna Han & Hyero Kim. (2020) Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea. Applied Health Economics and Health Policy 18:4, pages 557-566.
Crossref
Crossref
Jean-David Cohen, Sonia Tropé, Pascal Paubel, Audrey Munos & François Bocquet. (2020) Preconceived notions about biosimilars—a French experience. Clinical Rheumatology 39:8, pages 2251-2254.
Crossref
Crossref
Yujeong Kim, Hye-Young Kwon, Brian Godman, Evelien Moorkens, Steven Simoens & SeungJin Bae. (2020) Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?. Frontiers in Pharmacology 11.
Crossref
Crossref
A. Astier. (2020) Interchangeabilité et substitution des biosimilaires. Annales Pharmaceutiques Françaises 78:4, pages 277-284.
Crossref
Crossref
Johannes Schmailzl, Marcel W. Vorage & Hanno Stutz. (2020) Intact and middle‐down CIEF of commercial therapeutic monoclonal antibody products under non‐denaturing conditions. ELECTROPHORESIS 41:12, pages 1109-1117.
Crossref
Crossref
Evelien Moorkens, Steven Simoens, Per Troein, Paul Declerck, Arnold G. Vulto & Isabelle Huys. (2019) Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting. BioDrugs 33:3, pages 285-297.
Crossref
Crossref
Brian Chen, Sumimasa Nagai, James O. Armitage, Bartlett Witherspoon, Chadi Nabhan, Ashley C. Godwin, Y. Tony Yang, Anuhya Kommalapati, Sri Harsha Tella, Carlo DeAngelis, Dennis W. Raisch, Oliver Sartor, William J. Hrushesky, Paul S. Ray, Paul R. Yarnold, Bryan L. Love, LeAnn B. Norris, Kevin Knopf, Laura Bobolts, Joshua Riente, Stefano Luminari, Robert C. Kane, Shamia Hoque & Charles L. Bennett. (2019) Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. The Oncologist 24:4, pages 537-548.
Crossref
Crossref
Daniel C. Baumgart, Laurent Misery, Sue Naeyaert & Peter C. Taylor. (2019) Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. Frontiers in Pharmacology 10.
Crossref
Crossref
Emily LeonardMichael WascovichSonia OskoueiPaula GurzDelesha Carpenter. (2019) Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review. Journal of Managed Care & Specialty Pharmacy 25:1, pages 102-112.
Crossref
Crossref
Peter Schneider & Sabine Vogler. 2019. Medicine Price Surveys, Analyses and Comparisons. Medicine Price Surveys, Analyses and Comparisons
113
164
.
J. O’Callaghan, S. P. Barry, M. Bermingham, J. M. Morris & B. T. Griffin. (2018) Regulation of biosimilar medicines and current perspectives on interchangeability and policy. European Journal of Clinical Pharmacology 75:1, pages 1-11.
Crossref
Crossref
Sabine Vogler, Peter Schneider, Dimitra Panteli & Reinhard Busse. 2019. Arzneiverordnungs-Report 2019. Arzneiverordnungs-Report 2019
321
353
.
Eduardo Cazap, Ira Jacobs, Ali McBride, Robert Popovian & Karol Sikora. (2018) Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust. The Oncologist 23:10, pages 1188-1198.
Crossref
Crossref
Manoela Manova, Alexandra Savova, Maria Vasileva, Silvia Terezova, Maria Kamusheva, Daniela Grekova, Valentina Petkova & Guenka Petrova. (2018) Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis. Frontiers in Pharmacology 9.
Crossref
Crossref
Anna La Noce & Marcin Ernst. (2018) Switching from Reference to Biosimilar Products: An Overview of the European Approach and Real-World Experience So Far. EMJ Rheumatology, pages 74-81.
Crossref
Crossref
Jose-Manuel Carrascosa, Ira Jacobs, Danielle Petersel & Robert Strohal. (2018) Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. Dermatology and Therapy 8:2, pages 173-194.
Crossref
Crossref
Francisco J. Esteva, Justin Stebbing, Rebecca N. Wood-Horrall, Peter J. Winkle, Sung Young Lee & Sang Joon Lee. (2018) A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Cancer Chemotherapy and Pharmacology 81:3, pages 505-514.
Crossref
Crossref
Akos Ilias, Lorant Gonczi, Zuszsanna Kurti & Peter L. Lakatos. (2018) Biosimilars in ulcerative colitis: When and for who?. Best Practice & Research Clinical Gastroenterology 32-33, pages 35-42.
Crossref
Crossref
Andras Inotai, Marcell Csanadi, Guenka Petrova, Maria Dimitrova, Tomasz Bochenek, Tomas Tesar, Kristina York, Leos Fuksa, Alexander Kostyuk, Laszlo Lorenzovici, Vitaly Omelyanovskiy, Katalin Egyed & Zoltan Kalo. (2018) Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. BioMed Research International 2018, pages 1-9.
Crossref
Crossref
Molly Burich. 2018. Biosimilars. Biosimilars
49
73
.
Evelien Moorkens, Arnold G. Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Simon Keuerleber, Barbara Claus, Maria Dimitrova, Guenka Petrova, Ljiljana Sović-Brkičić, Juraj Slabý, Robin Šebesta, Ott Laius, Allan Karr, Morgane Beck, Jaana E. Martikainen, Gisbert W. Selke, Susan Spillane, Laura McCullagh, Gianluca Trifirò, Patricia Vella Bonanno, Asbjørn Mack, Antra Fogele, Anita Viksna, Magdalena Władysiuk, Helder Mota-Filipe, Dmitry Meshkov, Marija Kalaba, Simona Mencej Bedrač, Jurij Fürst, Corrine Zara, Peter Skiöld, Einar Magnússon & Steven Simoens. (2017) Policies for biosimilar uptake in Europe: An overview. PLOS ONE 12:12, pages e0190147.
Crossref
Crossref
Sophia Gran-Ruaz, Arvind Mani & Sherry O’Quinn. (2017) An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis. Multiple Sclerosis Journal 23:14, pages 1824-1829.
Crossref
Crossref
Paweł Kawalec, Ewa Stawowczyk, Tomas Tesar, Jana Skoupa, Adina Turcu-Stiolica, Maria Dimitrova, Guenka I. Petrova, Zinta Rugaja, Agnes Männik, Andras Harsanyi & Pero Draganic. (2017) Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries. Frontiers in Pharmacology 8.
Crossref
Crossref
Atanu Saha. (2018) Strategic Deterrence: An Application to Biologic Pharmaceuticals. SSRN Electronic Journal.
Crossref
Crossref